UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Animal models of Parkinson’s disease

The FEBS journal, 2012-04, Vol.279 (7), p.1156-1166

2012

Volltextzugriff (PDF)

Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model

The European journal of neuroscience, 2007-01, Vol.25 (2), p.397-405

2007

Volltextzugriff (PDF)

l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

Experimental neurology, 2014-03, Vol.253, p.180-191

2014

Volltextzugriff (PDF)

l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus

Neuropharmacology, 2014-04, Vol.79, p.90-100

2014

Volltextzugriff (PDF)

Transplantation of Undifferentiated Human Mesenchymal Stem Cells Protects against 6-Hydroxydopamine Neurotoxicity in the Rat

Cell Transplantation, 2010-02, Vol.19 (2), p.203-218

2010

Volltextzugriff (PDF)

Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats

Clinical and experimental pharmacology & physiology, 2015-06, Vol.42 (6), p.695-703

2015

Volltextzugriff (PDF)

Dual target strategy: combining distinct non‐dopaminergic treatments reduces neuronal cell loss and synergistically modulates l‐DOPA‐induced rotational behavior in a rodent model of Parkinson's disease

Journal of neurochemistry, 2015-08, Vol.134 (4), p.740-747

2015

Volltextzugriff (PDF)

Activation of the CREB/ c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer

Frontiers in cellular neuroscience, 2017-06, Vol.11, p.184-184

2017

Volltextzugriff (PDF)

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

Neurobiology of disease, 2006-04, Vol.22 (1), p.1-9

2006

Volltextzugriff (PDF)

Dopamine receptor agonists for Parkinson's disease

Expert opinion on investigational drugs, 2014-03, Vol.23 (3), p.387-410

2014

Volltextzugriff (PDF)

Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects

Stem cells translational medicine, 2015-09, Vol.4 (9), p.1073-1085

2015

Volltextzugriff (PDF)

The 6-hydroxydopamine model: News from the past

Parkinsonism & related disorders, 2008, Vol.14, p.S124-S129

2008

Volltextzugriff (PDF)

Search for cellular stress biomarkers in lymphocytes from patients with multiple sclerosis: a pilot study

PloS one, 2012-09, Vol.7 (9), p.e44935-e44935

2012

Volltextzugriff (PDF)

Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson’s disease

Apoptosis (London), 2012-03, Vol.17 (3), p.289-304

2012

Volltextzugriff (PDF)

Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors

Experimental cell research, 2010-04, Vol.316 (7), p.1148-1158

2010

Volltextzugriff (PDF)

Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease

Neurobiology of disease, 2011-09, Vol.43 (3), p.663-668

2011

Volltextzugriff (PDF)

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

Pharmacology & therapeutics (Oxford), 2011-12, Vol.132 (3), p.280-299

2011

Volltextzugriff (PDF)

New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

Expert opinion on investigational drugs, 2012-02, Vol.21 (2), p.153-168

2012

Volltextzugriff (PDF)

Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?

Frontiers in neurology, 2019-03, Vol.10, p.232-232

2019

Volltextzugriff (PDF)

Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia

Brain research, 2008-10, Vol.1238, p.215-223

2008

Volltextzugriff (PDF)

Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's Disease

Frontiers in neuroscience, 2017-05, Vol.11, p.306-306

2017

Volltextzugriff (PDF)

Activation of brain metabolism and fos during limbic seizures: The role of Locus Coeruleus

Neurobiology of disease, 2008-06, Vol.30 (3), p.388-399

2008

Volltextzugriff (PDF)

Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease

Brain research, 2010-01, Vol.1311, p.12-27

2010

Volltextzugriff (PDF)

Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease

Biochimica et biophysica acta, 2014-09, Vol.1842 (9), p.1385-1394

2014

Volltextzugriff (PDF)

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l -DOPA-induced dyskinesias in a rodent model of Parkinson's disease

Neurobiology of disease, 2008-01, Vol.29 (1), p.161-168

2008

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(55)
Buchkapitel
(1)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Animal models of Parkinson’s disease

Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model

l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus

Transplantation of Undifferentiated Human Mesenchymal Stem Cells Protects against 6-Hydroxydopamine Neurotoxicity in the Rat

Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats

Dual target strategy: combining distinct non‐dopaminergic treatments reduces neuronal cell loss and synergistically modulates l‐DOPA‐induced rotational behavior in a rodent model of Parkinson's disease

Activation of the CREB/ c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

Dopamine receptor agonists for Parkinson's disease

Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects

The 6-hydroxydopamine model: News from the past

Search for cellular stress biomarkers in lymphocytes from patients with multiple sclerosis: a pilot study

Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson’s disease

Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors

Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?

Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia

Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's Disease

Activation of brain metabolism and fos during limbic seizures: The role of Locus Coeruleus

Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease

Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l -DOPA-induced dyskinesias in a rodent model of Parkinson's disease

Suchergebnisse filtern